US4024255A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tetrazole containing naphthyridine-3-carboxamides
Assignee: Allen and Hanburys Ltd
•
Filing: 1975-09-25
•
Granted: 1977-05-17
•
Expires: 1995-09-25
Abstract
Abstract Compounds of the general formulae I and II and pharmaceutically acceptable salts thereof: ##STR1## in which: R 1 represents a hydrogen atom, a halogen atom, an alkenyl or alkyl group; or a group OR 3 or NR 3 R 4 where R 3 and R 4 which may be the same or different and may represent a hydrogen atom, or an alkenyl group, or an alkyl group which alkyl group may optionally be substituted by one or more hydroxy, alkoxy, acyloxy, aryl, amino, alkylamino, dialkylamino, diaralkylamino or alkylaralkylamino groups; or R 3 and R 4 together with the nitrogen atom form a 5 or 6 membered heterocyclic ring that may optionally contain other hetero atoms. R 2 has the same meanings as R 3 . The compounds have utility for the treatment of conditions in which combination of an antigen with a reaginic antibody is primarily responsible.
Inventors
- 👤 Gwynn Pennant Ellis
- 👤 Ian Collins
- 👤 David Martin Waters
- 👤 David Edmund Bays
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 12:03
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/535; C; C07; C07D; C07D471/00; C07D471/02; C07D471/04
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
92 words
A compound of the formula ##STR5## or the formula ##STR6## in which R 1 represents pyrrolidinyl, piperidino, morpholino, piperazinyl or N-methyl-piperazinyl group, and R 2 represents a hydrogen atom, a C 2-6 alkenyl group, a C 1-6 alkyl group, a C 1-6 alkyl group substituted by at least one hydroxy, C 1-6 alkoxy group, C 1-6 alkanoyloxy, phenyl, amino, C 1-6 alkylamino, di C 1-6 alkylamino, diphenyl C 1-6 alkylamino or N,C 1-6 alkyl, N-phenyl C 1-6 alkylamino group; or a pharmaceutically acceptable salt of a compound of formula I or II.
Claim 2
Dependent Claim
92 words
A compound of the formula ##STR5## or the formula ##STR6## in which R 1 represents pyrrolidinyl, piperidino, morpholino, piperazinyl or N-methyl-piperazinyl group, and R 2 represents a hydrogen atom, a C 2-6 alkenyl group, a C 1-6 alkyl group, a C 1-6 alkyl group substituted by at least one hydroxy, C 1-6 alkoxy group, C 1-6 alkanoyloxy, phenyl, amino, C 1-6 alkylamino, di C 1-6 alkylamino, diphenyl C 1-6 alkylamino or N,C 1-6 alkyl, N-phenyl C 1-6 alkylamino group; or a pharmaceutically acceptable salt of a compound of formula I or II.
Claim 3
Dependent Claim
13 words
The compound of claim 1 wherein R 2 is piperidino, morpholino or N-methyl-piperazinyl.
Claim 4
Dependent Claim
10 words
A compound as claimed in claim 1 which is 1-ethyl-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-N(1H-tetrazol-5-yl)-1,8-naphthyridine-3-carboxamide.
Claim 5
Dependent Claim
10 words
A compound as claimed in claim 1 which is 1-ethyl-1,4-dihydro-7-morpholino-4-oxo-N(1H-tetrazol-5-yl)-1,8-naphthyridine-3-carboxamide.
Claim 6
Dependent Claim
10 words
A compound as claimed in claim 1 which is 1-ethyl-1,4-dihydro-4-oxo-7-piperidine-N(1H-tetrazol-5-yl)-1,8-naphthyridine-5-carboxamide.
Claim 7
Dependent Claim
61 words
A pharmaceutical composition for treating conditions due to a combination of an antigen with a reaginic antibody in which the condition is extrinsic asthma, hay fever, urticaria, exzema or atopic dermatitis comprising an effective amount of a compound as claimed in claim 1 if desired in the form of a pharmaceutically acceptable salt together with an inert pharmaceutical carrier or diluent.
Claim 8
Dependent Claim
75 words
A method of treating a patient suffering from or liable to a condition resulting primarily from the combination of an antigen with a reaginic antibody in which the condition is extrinsic asthma, hay fever, urticaria, exzema or atopic dermatitis which comprises administering to said patient by oral ingestion or inhalation an effective amount of a compound as claimed in claim 1, if desired in the form of a pharmaceutically acceptable salt to alleviate said condition.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-05-16 | 1980-11-15 | 1981-05-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-05-16 | 1984-11-15 | 1985-05-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-05-16 | 1988-11-15 | 1989-05-17 | $7700.00 | Window Closed / Lapsed |